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1. Introduction
Telomeric DNA consists of repetitive DNA sequences
(TTAGGG) at the ends of chromosomes and contributes
to genomic stability. Telomerase is a ribonucleoprotein
composed of the catalytic subunit of human telomerase
reverse transcriptase (hTERT) and telomerase RNA
component and elongates telomeric DNA [1]. It has been
known that telomerase is involved in establishing cellular
immortalization [2] and is described to contribute to on-
cogenic event because of expression of telomerase in
cancer cell. Its activity is observed in more than 80% of
clinical samples from head and neck squamous cell carci-
nomas using telomeric repeat amplification protocol
(TRAP) assay [3–7]. TRAP was tested in tissue or
mouthwash from patients carrying leukoplakia as a pre-
cancerous lesion [4, 5]. Moreover, hTERT mRNA expres-
sion is elevated in cancer cells having telomerase activity
[6]. Therefore, telomerase activity is expected to be
a useful marker in cancer detection.
Although TRAP assay is conventional method to
detect a telomerase activity, this method requires several
tedious steps and it is difficult to provide objective evalu-
ations of its activity [8]. To overcome this problem, novel
telomerase detecting methods have been developing and
these are containing PCR- and/or gel electrophoresis-free
technique [9]. For example, telomerase activity detection
was monitored by the wavelength change of Surface Plas-
mon Resonance on the telomerase substrate (TS) primer-
immobilized on silicon microsensing chip before and after
telomerase treatment [10]. Since electrochemical tech-
nique is expected to provide a simple and rapid method
[11], electrochemical telomerase assay has been studied
by several researchers [9, 12,13]. It has been reported
that electrochemical signal was decreased after telomer-
ase elongation of TS primer-immobilized electrode hy-
bridized with its complementary ferrocenyloligonucleo-
tide [12]. The former or latter technique provides high
sensitivity of 10 HeLa cells/mL or 0.1 HeLa cells/mL (100
HeLa cells/mL), respectively. We have been developing
an electrochemical telomerase assay (ECTA), which con-
sists TS primer-immobilized electrode coupled with ferro-
cenylnaphthalene diimide as telomere DNA ligand
(Scheme 1) [13]. This method provides simple and rapid
screening with the detection limit of 0.4 HeLa cells/mL
(10 cells in 25 mL of sample solution) [13]. Exfoliated cell
and tissue from healthy and cancer individuals were
tested by ECTA and high positive rate of 85% and 90%,
respectively. In clinical site, it is required the discrimina-
tion of cancer patient from patient suffered from oral dis-
ease rather than healthy one evaluating by patients with
a disease who test positive and patients without a disease
who test negative. For example, detection of gastric and
cervical cancers is generally carried out using gastric pho-
tofluorography with barium [14] and cytology [15], re-
spectively. These detection methods have a relative high
sensitivity and specificity from 80% to 95%.
One benefit of diagnosing oral lesions for other inter-
nal one is to achieve by gross inspection and palpation.
Since oral cancer recognizes by patient as well as special-
ist, this finding is often delayed for the following two rea-
sons: (i) Patient doesnt have a distinguishing subjective
symptoms before his cancer progresses [16] and (ii)
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Abstract : Electrochemical telomerase assay (ECTA) de-
veloped by our group was evaluated in an oral cancer
screening using exfoliated oral cells and tissues obtained
from patients of oral cancer, mucosa associated disease,
or healthy volunteers. Telomerase activity from ECTA is
correlated with hTERT mRNA expression level using
a real-time PCR and was increasing in the following
order: healthy volunteer group<mucosa associated dis-
ease group<oral cancer group. Sensitivity and specificity
of ECTA were 88% and 72%, respectively when used
17% of the threshold value based on the receiver operat-
ing characteristic curve in ECTA data.
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Aspect of oral cancer or precancerous lesions was often
confused with oral leukoplakia or oral lichen planus be-
cause of similarity of their color and form [17]. Therefore,
it is difficult to distinguish oral cancer or precancerous le-
sions under early stage. Delayed cancer diagnosis leads to
a delayed treatment resulting in a severe surgical stress,
dysfunction, and decreasing the 5-year survival rates [18].
Therefore, necessity in the cancer detection for various
oral lesions is growing and the detection method with
simple, rapid, and minimal invasive procedure.
Our previous researches succeed cancer diagnosis for
cancer and healthy individuals. However, it is important
to detect cancer patients from patients suffered from
mucosa-associated disease including precancerous lesion
[19,20]. Here, we analyzed the expression levels of
hTERT mRNA and evaluated telomerase activity with
ECTA for same clinical sample. Furthermore, we aimed
to detect oral cancer using ECTA as a simple, rapid, and
minimal invasive technique with clinical samples obtained
from patients with oral cancer or mucosa-associated dis-
ease and healthy volunteers. Furthermore, we evaluated
the usefulness of cancer diagnosis with calculation of sen-
sitivity and specificity.
2. Experimental
2.1 Collection of clinical samples
This study was approved by the ethics committee of
Kyushu Dental University (approval no. 12–37). Samples
were collected at the Department of Oral and Maxillofa-
cial Surgery, Kyushu Dental University Hospital (Fukuo-
ka, Japan) between 2010 and 2013 from 30 patients with
oral cancer, 30 patients with mucosa-associated disease
(leukoplakia or oral lichen planus), and 30 healthy volun-
teers after obtaining informed consent. All patients with
oral cancer were diagnosed with squamous cell carcinoma
(SCC), and patients with mucosa-associated disease were
diagnosed by histopathological analysis (Tables S1–6).
Exfoliated oral cells (EOCs) and tissues were collected
from each participant as clinical samples. The EOCs were
collected by scratching the buccal mucosa and the tongue
on the right and left sides five times each with a sponge-
type brush regardless of the location of the lesions. The
collected cells were suspended in 20 mL saline and then
centrifuged at 10,000 rpm (91,000g) for 5 min at 48. The
obtained pellets were mixed with 500 mL of lysis buffer
(10 mM Tris-HCl (pH7.5), 1 mM MgCl2, 1 mM EGTA,
0.1 mM Benzamidine, 5 mM b-mercaptoethanol, 0.5%
CHAPS, 10% Glycerol) and stored at 808. This collec-
tion method is similar to a self-screening method that
anyone can perform easily, even if the individual is not
aware of the presence of lesions. Tissues measuring about
1.01.01.0 mm were collected by surgical resection or
biopsy. In healthy volunteers, samples of the same size
were collected from the buccal mucosa or the tongue.
After collection, 500 mL of lysis buffer was added to each
sample, and samples were stored at 808. Before the
assay, lysates were centrifuged at 10,000 rpm (91,000g)
for 10 min at 48, and supernatants were collected. The
protein concentrations of the supernatants were deter-
mined based on absorbance at 280 nm using an ND-1000
instrument (NanoDrop Technologies, Wilmington, DE,
USA).
2.2 Analysis of the expression levels of hTERT mRNA
Total RNA was extracted from clinical samples using an
RNeasy kit (Qiagen GmbH, Hilden, Germany), and
cDNAs were synthesized using a QuantiTect Reverse
Transcription Kit (Qiagen), according to the manufactur-
ers protocol. cDNAs were then subjected to polymerase
chain reaction using a QuantiTect SYBR GREEN PCR
kit (Qiagen) and MX3005P instrument (Agilent, Santa
Clara, CA, USA). Thermal cycling was carried out under
the following conditions: 958 for 15 min; 40 cycles of 948
for 15 s, 558 for 30 s, and 728 for 30 s. The expression
level of hTERT mRNA was calculated using the follow-
ing formula (1).
DCt ¼ CtðhTERTÞ=CtðGAPDHÞ ð1Þ
Scheme 1. FND (A) based electrochemical telomerase assay,
ECTA (B).
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Reverse transcription (RT)-PCR primers were custom
synthesized by Genenet (Fukuoka, Japan). The sequences
were as follows [21]: hTERT, forward primer 5’-GGAG-
CAAGTTGCAAAGCATTG-3’ and reverse primer 5’-
TCCCACGACGTAGTCCATGTT-3’; glyceraldehyde
phosphate dehydrogenase (GAPDH), forward primer 5’-
ATGGAAATCCCATCACCATCTT-3’ and reverse
primer 5’-CGCCCCACTTGATTTTGG-3’ [14].
2.3 ECTA
ECTA was carried out using an ALS/CHI Electrochemi-
cal Analyzer Model 650A (CH Instrument, Austin, TX,
USA). Briefly, 25 mL elongation reaction solution (40 ng/
mL lysate, 50 mM Tris(hydroxymethyl)aminomethane-
HCl [pH 8.0], 1.0 mM MgCl2, 50 mM KCl, 0.10 mM 2-
mercaptoethanol, 0.10 M spermidine, and 20 mM dNTP
mixture) was placed on a T8TS1 immobilized electrode
manufactured by Sato et al. [22] after multipotential step,
SWV measurements as i0 measurements. The electrode
was then incubated at 37 8C for 30 min and washed with
350 mL Milli-Q water, 1 phosphate-buffered saline
(PBS), and 0.1 M acetic acid-potassium acetate (AcOK-
AcOH) containing 0.1 M KCl. Next, 350 mL of 20 mM
FND (N,N’-bis[[4-(3-ferrocenepropionamidopropyl)-pi-
perazin-1-yl]propyl]-naphthalene- 1,4,5,8-tetracarboxylic
acid diimide) [23] (Scheme 1A), 0.1 M AcOK-AcOH, and
0.1 M KCl solution was placed on the electrode. Electro-
chemical measurements were carried out using multipo-
tential step, SWV measurements (i measurements) [13]
(Scheme 1B). The data were evaluated according to the
following formula (2):
Di % ¼ ðii0Þ=i0 ð2Þ
2.4 Statistical analysis
The results of hTERT mRNA expression and ECTA were
analyzed using Kruskal Wallis tests and the Steel-Dwass
method. All analyses were performed using Microsoft
Excel 2010 (Microsoft Corporation, Redmond, WA,
USA). Differences with p values of less than 0.05 were
considered significant.
3. Results and Discussion
First, we analyzed the expression levels of hTERT
mRNA obtained from 15 patients with oral cancer, 15 pa-
tients with mucosa-associated disease, and 15 healthy vol-
unteers (Tables S1–3). As shown in Figure 1A, the rela-
tive expression of hTERT mRNA in EOCs was highest in
patients with oral cancer, followed by patients with
mucosa-associated disease. Significant differences in ex-
pression were observed between healthy volunteers and
patients with mucosa-associated disease (p<0.01) and be-
tween healthy volunteers and patients with oral cancer
(p<0.01). Similar trends were observed for tissue sam-
ples, with expression levels highest in patients with oral
cancer and lowest in healthy volunteers (Figure 1B). Sig-
nificant differences were observed between healthy vol-
unteers and patients with oral cancer (p<0.01) and be-
tween patients with mucosa-associated disease and pa-
tients with oral cancer (p<0.05).
Next, we analyzed telomerase activity by ECTA using
clinical samples from 30 patients with oral cancer, 30 pa-
tients with mucosa-associated disease, and 30 healthy vol-
unteers (Tables S4–6). In EOCs, telomerase activity was
highest in patients with oral cancer (27%), followed by
patients with mucosa-associated disease (17%) and
healthy volunteers (8.3%; Figure 2A). Comparisons be-
tween groups demonstrated that all differences were stat-
istically significant. Similar trends were observed in tis-
sues, with highest telomerase activity observed in patients
with oral cancer (24%), followed by patients with
mucosa-associated disease (13%) and healthy volunteers
(12%; Figure 2B). Significant differences were observed
between healthy volunteers and patients with oral cancer
and between patients with mucosa-associated disease and
patients with oral cancer (p<0.01). These results were
Fig. 1. hTERT mRNA expression in EOCs (A) (*: p<0.01)
and tissue (B) (*: p<0.01, **: p<0.05).
Fig. 2. Current increases in EOCs (A) (*: p<0.01) and tissues
(B) (*: p<0.01).
www.electroanalysis.wiley-vch.de  2015 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Electroanalysis 2015, 27, 1 – 6 &3&
These are not the final page numbers! 
Full Paper
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
58 58
consistent with the results of hTERT mRNA expression
levels in the different groups.
Finally, based on the results of ECTA, we performed
receiver operating characteristic (ROC) curve analysis to
detect oral cancer from the clinical samples obtained in
this study. High effectiveness is indicated by higher values
for the area under the ROC curve (AUC; nearing 1). The
results for the AUC were 0.85 in EOCs (Figure 3, *), 0.82
in tissues (Figure 3, *), and 0.83 in all samples combined
(Figure 3, D). The threshold value determined using ROC
curves was 17% telomerase activity as detection of oral
cancer was achieved with 16.2% activity in EOCs, 17%
activity in tissues, and 16.5% in all samples. Thus, less
than 17% activity was considered negative, while more
than 17% activity was considered positive. As shown in
Table 1, the sensitivities for detection of telomerase activ-
ity in EOCs and tissues using ECTA were 90% and 87%,
respectively, and the specificity was 72%. From these
data, the false-positive rate was 28%, and the false-nega-
tive rates were 10% and 13% for EOCs and tissues, re-
spectively. Furthermore, in all samples, the sensitivity was
88%, the specificity was 72%, the false-positive rate was
28%, and the false-negative rate was 12%.
In this study, we analyzed hTERT mRNA expression
levels by RT-PCR and evaluated telomerase activity with
ECTA using clinical samples (EOCs and tissues) obtained
from patients with oral cancer, patients with mucosa-asso-
ciated disease, and healthy volunteers. Our data showed
that ECTA and analysis of hTERT expression could pre-
dict the presence of oral cancer.
Some researchers have shown that expression of
hTERT mRNA increases as the histological stage of oral
carcinogenesis becomes more advanced [24,25]. In our
study, the results showed that patients with oral cancer
exhibited the highest level of hTERT expression, followed
by patients with mucosa-associated disease and finally
healthy volunteers, consistent with previous reports. Fur-
thermore, we subsequently confirmed the correlation be-
tween telomerase activity, as measured using ECTA, and
hTERT mRNA expression.
Similar to the results of hTERT expression, telomerase
activity was highest in patients with oral cancer and
lowest in healthy volunteers, consistent with a previous
report [14]. Additionally, telomerase activity of patients
with mucosa-associated disease was moderate compared
with the other groups. Mucosa-associated disease may
result in oral cancer, although this outcome is not always
observed. Although we were not attempting to distinguish
oral cancer from mucosa-associated disease, our study did
reveal that ECTA could detect oral cancer from all sam-
ples based on high sensitivity and specificity. Moreover,
our data indicated that telomerase activity, as measured
using ECTA, may be associated with hTERT mRNA ex-
pression. Thus, telomerase activity in patients with
mucosa-associated disease, which may transform into oral
cancer in the future, can be also detected with ECTA.
Furthermore, clinical samples showing dramatic increases
in telomerase activity may have a greater tendency to
transform in oral cancer. Therefore, these data suggest
that ECTA may be applicable for evaluation and diagno-
sis of carcinogenesis [3,26,27].
We used both tissue samples and EOCs because we as-
sumed that clinical samples would vary in cell numbers
and contain both normal cells and cells from any lesions
present in the oral cavity. However, the results of ROC
analysis revealed that ECTA with EOCs showed slightly
increased telomerase activity that tissues and that the
method was highly sensitive and specific. Thus, these re-
sults indicates that EOCs provided a highly reliable speci-
men for screening, enabling simple evaluation of the
entire oral cavity, regardless of whether a known lesion is
present. Furthermore, both the false-negative and false-
positive rates were low. The low false-negative rate
showed that EOCs, which could be collected using nonin-
vasive, simple methods, yielded results similar to those of
tissues. It is generally considered necessary to collect spe-
cific tissues in order to reach a definitive diagnosis; how-
ever, such tissue collection is often invasive and painful.
Therefore, this method is appropriate for self-examina-
tion screening by scratching of the entire oral cavity. On
the other hand, the false-positive rate was slightly higher
than 20%; this may be caused by high telomerase activity
resulting from inflammation with infiltration of lympho-
cytes or necrotic tissues in clinical samples [28,29]. There-
fore, depending on the results of such examinations, it is
Fig. 3. ROC analysis of EOCs (*), tissues (*), and all samples
(D).
Table 1. Sensitivity, specificity, false-positive rate, and false-nega-
tive rate
Sensitivity Specificity False-positive
rate
False-negative
rate
EOC 90% 72% 28% 10%
T 87% 72% 28% 13%
All sam-
ples
88% 72% 28% 12%
EOC: exfoliated oral cells; T: tissues
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important to pursue an accurate diagnosis by a medical
specialist.
4. Conclusions
In summary, our study showed that EOCs and tissues
from the oral cavity could be used for diagnosis of oral
cancer by ECTA. ECTA allowed for early detection of
cancer, which is imperative for improved treatment out-
comes. Furthermore, ECTA represents a promising ex-
amination method which could be applied to other fluid
samples, such as urine or sputum.
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